ArticleJournal of the American Heart Association2025
Timing and Mode of Death Following Treatment of Neonatal Symptomatic Tetralogy of Fallot.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeonates with tetralogy of Fallot and symptomatic cyanosis (sTOF) require early intervention, using a staged or primary repair strategy. Postprocedural mortality risk within this group is considerable. The mode of death and associated factors have been inadequately defined in early childhood mortality following treatment of sTOF. This study aims to describe the timing, cause, and associated risk factors of postprocedural death in infants with sTOF.
methodsNeonates with sTOF who had an initial intervention from 2005 to 2017 at 9 centers of the Congenital Cardiac Research Collaborative were reviewed. Among nonsurvivors, details regarding timing, cause of death, and last follow-up were obtained. Patient characteristics between survivors and nonsurvivors were compared.
resultsOf 572 patients with sTOF (230 primary repair, 342 staged repair), 52 (9%) died at a median age of 82 (25th-75th%ile: 28-246) days. Death was perioperative (≤30 days) in 52% of cases. Most deaths were cardiac (69%, n=36), with heart failure and sudden death being most common. Noncardiac causes included necrotizing enterocolitis (n=3), infectious (n=3), and intracranial hemorrhage (n=2). Risk factors for mortality included prematurity, low birth weight, genetic syndrome, race categorized as other, noncardiac anomaly, and ventilation before initial intervention (
conclusionsWhen death occurs after interventions for sTOF, it frequently occurs early and relates to traditional risk factors. Sudden death is a prominent cause of mortality following discharge from definitive repair.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.